Figure 3.

Combined anti-PD-L1 mAb and ALA-PDT therapies are associated with an increased number of tumor-infiltrating lymphocytes. (a-b) Relative mRNA expression was detected by qPCR (n = 5 for each group). (c-d) Tumors were collected from each treatment group, and single-cell suspensions were prepared and then stained for specific antibodies against immune cell surface markers (n = 3 for each group). The average percentage of positive surface markers for each group was calculated using flow cytometry. *p < 0.05, **p < 0.01.